Home / Research library / BPC-157
Compound guide
BPC-157: what the research covers
A fifteen-residue fragment of a gastric protective protein, studied for angiogenic signalling and gut-lining effects. What BPC-157 is, what the literature actually examines, and how it is supplied.
What BPC-157 is
BPC-157 is a synthetic pentadecapeptide — fifteen amino acids, sequence GEPPPGKPADDAGLV — corresponding to a partial sequence of body protection compound, a protein identified in human gastric juice. It does not occur in that isolated form in the body; it is a fragment synthesised because the fragment, rather than the parent protein, carries the activity that interested the original investigators.
Two properties make it unusual among research peptides. It is stable in gastric acid, which is rare for a peptide of any length and is why much of the published work uses oral administration in animal models where an equivalent sequence would simply be digested. And it has no established receptor. After three decades of study the binding target remains uncharacterised, which is a genuine gap rather than a detail, and it means the mechanistic literature is built on downstream observations rather than on receptor pharmacology.
What the literature examines
The largest body of work concerns angiogenesis. BPC-157 has been reported to upregulate VEGFR2 expression and to activate downstream signalling through the VEGFR2-Akt-eNOS pathway, and the vascular response is the mechanism most consistently invoked to explain findings across otherwise unrelated tissue models.
A second strand concerns the gastrointestinal tract, which reflects the compound's origin. Work here covers mucosal integrity, tight-junction protein expression and models of induced injury. A third concerns tendon, ligament and muscle models, where the reported outcomes are usually framed in terms of fibroblast migration and collagen organisation. There is also a smaller nitric-oxide and dopaminergic literature.
The honest summary of the evidence base is that it is substantial in rodent models and close to absent in controlled human trials. Anyone designing work with this compound should read the primary literature rather than secondary summaries of it, because the gap between what the animal studies show and what is often claimed on the basis of them is wide. Published work is indexed on PubMed.
How Amino Club supplies it
BPC-157 is supplied as a lyophilised acetate salt in sealed vials — BPC-157 — and as a metered 15ml intranasal preparation, BPC-157 nasal spray, where no reconstitution step is needed. It is also available combined with TB-500 as the BPC-157 / TB-500 preparation and its intranasal form.
Every batch is specified at 99% purity or better by HPLC with identity confirmed by mass spectrometry, and is released only against the Certificate of Analysis carrying the batch number printed on the vial. The lab testing page documents that process. Purity matters more here than the figure alone suggests: truncated synthesis products in a fifteen-residue sequence are difficult to separate and can carry their own activity.
The lyophilised form is stable at ambient temperature in transit and held at -20°C for long-term storage. Reconstitution notes are on the product page; solvents are under reconstitution supplies.
Related reading
BPC-157 and TB-500 are routinely studied together and routinely confused; the BPC-157 versus TB-500 comparison sets out what separates them. Both sit in the tissue and repair group alongside TB-500, KPV, LL-37 and ARA-290.
The research library indexes every guide on this site. Certificate and storage questions are answered on the FAQ; quantity pricing through bulk and wholesale.
Research use only
BPC-157 supplied by Amino Club is a laboratory reference material. It is not a medicine, not a supplement, and not for human or veterinary use, and no dosing guidance or administration protocol is provided. The full terms are in the research use policy.